• Explore /
  • Poster
  • / Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial.

Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial.

Abstract Poster

Authors

null

Dongming Liu

Liver Cancer Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China

Dongming Liu , Han Mu , Changfu Liu , Weihao Zhang , Yunlong Cui , Qiang Wu , Xiaolin Zhu , Feng Fang , Wei Zhang , Wenge Xing , Qiang Li , Tianqiang Song , Wei Lu , Huikai Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT05029973

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4073)

DOI

10.1200/JCO.2022.40.16_suppl.4073

Abstract #

4073

Poster Bd #

61

Abstract Disclosures

Similar Posters

First Author: Miao Wang

First Author: Jaekyung Cheon

First Author: Han Chong Toh

First Author: Dieter Koeberle